Effects of estetrol/drospirenone on self-reported physical and emotional premenstrual and menstrual symptoms: Data from the phase 3 clinical trial in the United States and Canada
In first time pill users, the estetrol/drospirenone containing oral contraceptive significantly reduces menstrual pain, premenstrual and menstrual water retention and premenstrual negative affect. In those switching from another pill, the menstrual-related distress symptoms remain stable.
Authors
- Melissa J. Chen (ORCID: https://orcid.org/0000-0002-4569-5614)
- Mitchell D. Creinin (ORCID: https://orcid.org/0000-0001-5967-8180)
- Maud Jost
- Jeffrey T. Jensen (ORCID: https://orcid.org/0000-0002-4733-1224)
- Johannes Bitzer (ORCID: https://orcid.org/0000-0001-7505-0684)
- Andrew M. Kaunitz
- Jean-Michel Foidart
- Céline Bouchard (ORCID: https://orcid.org/0000-0003-2258-058X)
Institutions
- University of Liège (BE)
- Oregon Health & Science University (US)
- University Hospital of Basel (CH)
- University of Florida (US)
- Canadian Women's Health Network (CA)
- Quebec - Clinical Research Organization in Cancer (CA)
- University of California, Davis (US)
- Florida College (US)
Publication Details
- Journal
- Contraception
- Published
- 2025-03-20
- DOI
- https://doi.org/10.1016/j.contraception.2025.110889
- Citations
- 1
- Primary Topic
- Menstrual Health and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.88